PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer

Completed · Early Phase 1

Conditions studied: Bladder Cancer

In brief

Approximately 25 subjects will be enrolled and receive a standard WHO adult potency BCG immunization (1cc/50mg live mycobacilli) in the deltoid. Following a wait period after BCG vaccination, patients will then receive standard strength BCG intravesical therapy once a week for a total of 6 weeks. The BCG is instilled and held in the bladder for approximately 2 hours. While the BCG is retained in the bladder the patient should be repositioned every 30 minutes to maximize bladder surface exposure to the agent. Patients will undergo a cystoscopy every 3 months following most recent TURBT. Study duration last approximately 6 months.

Key facts

Study ID
NCT02326168
Run by
The University of Texas Health Science Center at San Antonio
People needed
25
Starts
2013-10-01
Expected to finish
2015-10-01
Last updated by the study team
2017-01-25

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.